Following the announcement today by New Zealand’s Prime Minister that the COVID-19 alert status will be raised to Level 4 in 48 hours time, Fisher & Paykel Healthcare Corporation Limited advises that it has been designated an essential service by the New Zealand Government and will continue operations in its Auckland facilities.
“As we advised last week, we have ramped up our manufacturing output and this will continue under the Level 4 alert status. As an essential service, we are continuing to focus on meeting the global demand for our respiratory products that are directly involved in treating patients with COVID-19,” said Managing Director and CEO Lewis Gradon.
“We are very appreciative of the support that we have received from our suppliers to date. We ask them to continue to work with us, as essential suppliers of raw materials, components, logistics and other services that are directly required for us to manufacture and supply critical respiratory products.
“We have already enabled remote working for our employees who are not directly critical to our manufacturing and supply operations. This has reduced the number of people in our offices, cafeterias and other common spaces. Our aim is to create a work environment that is as safe as possible for the people whose jobs require being on site. We have already implemented extra cleaning and sanitisation measures and social distancing protocols.
“This is a rapidly changing situation. We are monitoring any developments closely and will proactively share further updates as we are able. I want to again acknowledge the tireless efforts of our people all around the world during this challenging time,” said Mr Gradon.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Investor Relations Manager
+64 (0) 27 807 8073
Senior Communications Manager
+64 (0) 21 713 911
VP Corporate & Company Secretary.
Fisher & Paykel Healthcare confirms status as essential service
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment